21.505  0.025 (0.12%)		01-14 11:20
Open: 21.49 High: 21.54 Volume: 670,391		Pre. Close: 21.48 Low: 21.48 Market Cap: 2,080(M)

Short term
Mid term
Targets	6-month :	25.32	1-year :	29.57
Resists	First :	21.68	Second :	25.32
Pivot price	21.52
Supports	First :	21.43	Second :	21.29
MAs	MA(5) :	21.48	MA(20) :	21.5
	MA(100) :	18.5	MA(250) :	12.91
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	35.5	D(3) :	37.2
RSI	RSI(14): 57.2
52-week	High :	23.56	Low :	6.38

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AVDL ] has closed above bottom band by 26.5%. Bollinger Bands are 95.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	21.57 - 21.7	21.7 - 21.8
Low:	21.14 - 21.31	21.31 - 21.43
Close:	21.26 - 21.51	21.51 - 21.68

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Wed, 14 Jan 2026
FIL Limited discloses 3.14% stake in Avadel Pharmaceuticals By Investing.com - Investing.com UK

Wed, 14 Jan 2026
Morgan Stanley discloses dealings in Avadel Pharmaceuticals shares By Investing.com - Investing.com Australia

Mon, 12 Jan 2026
Avadel Shareholders Approve Acquisition by Alkermes plc - TipRanks

Mon, 12 Jan 2026
Avadel Pharmaceuticals plc Approves Scheme of Arrangement for Alkermes Acquisition - Quiver Quantitative

Mon, 12 Jan 2026
Shareholders back Avadel sale to Alkermes after strong vote - Stock Titan

Fri, 09 Jan 2026
Do Options Traders Know Something About Avadel Pharmaceuticals Stock We Don't? - TradingView — Track All Markets

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	98 (M)
Shares Float	81 (M)
Held by Insiders	1 (%)
Held by Institutions	94.6 (%)
Shares Short	2,910 (K)
Shares Short P.Month	6,650 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1
Profit Margin	-0.2 %
Operating Margin	2.5 %
Return on Assets (ttm)	-0.4 %
Return on Equity (ttm)	-0.4 %
Qtrly Rev. Growth	54.9 %
Gross Profit (p.s.)	2.4
Sales Per Share	2.53
EBITDA (p.s.)	0.02
Qtrly Earnings Growth	0 %
Operating Cash Flow	35 (M)
Levered Free Cash Flow	3 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	21.27
Price to Sales	8.48
Price to Cash Flow	61.05

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.